Vor Biopharma Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2023 Annual Meeting of Stockholders held by Vor Biopharma Inc. on May 26, 2023. The company is an emerging growth company incorporated in Delaware, with its principal executive offices in Cambridge, Massachusetts.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes and Voting Results
Approximately 87% of the shares entitled to vote (58,300,172 shares) were represented at the meeting. Stockholders voted on two proposals:
- Proposal 1: Election of Directors
- David C. Lubner: Elected with 53,754,258 votes for, 45,048 votes withheld, and 4,500,866 broker non-votes.
- Joshua Resnick, M.D.: Elected with 44,270,251 votes for, 9,529,055 votes withheld, and 4,500,866 broker non-votes.
- Proposal 2: Ratification of Auditors
- Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2023.
- Votes: 58,294,758 For, 1,908 Against, 3,506 Abstentions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management commentary on future outlook, specific risks, contingencies, or unusual items. Detailed descriptions of the proposals are referenced in the definitive proxy statement on Schedule 14A filed on April 14, 2023.
Key Facts for Investor Verification
- Verify the tenure of the newly elected directors (David C. Lubner and Joshua Resnick, M.D.) through the 2026 Annual Meeting.
- Confirm the high level of shareholder participation (87% representation) and the significant number of broker non-votes on director elections.
- Note the substantial number of votes withheld for Joshua Resnick, M.D. (9,529,055) compared to David C. Lubner (45,048).
- Review the Schedule 14A proxy statement for detailed context on the director nominees and auditor selection.